Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors

Sara Elena Rebuzzi; Arsela Prelaj; Alex Friedlaender; Alessio Cortellini; Alfredo Addeo; Carlo Genova; Abdul Rafeh Naqash; Edouard Auclin; Laura Mezquita; Giuseppe Luigi Banna

doi:10.1016/j.critrevonc.2022.103806

Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors

Crit Rev Oncol Hematol. 2022 Nov:179:103806. doi: 10.1016/j.critrevonc.2022.103806. Epub 2022 Sep 8.

Authors

Affiliations

¹ Medical Oncology Unit, Ospedale San Paolo, Savona, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy.
² Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy.
³ Department of Oncology, Clinique Générale Beaulieu, Geneva, Switzerland; Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.
⁴ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
⁵ Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.
⁶ Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy; UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁷ Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA.
⁸ Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France.
⁹ Medical Oncology Department, Hospital Clinic of Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Spain; Department of Medicine, University of Barcelona, Spain.
¹⁰ Portsmouth Hospitals University NHS Trust, Portsmouth, UK. Electronic address: [email protected].

PMID: 36087850
DOI: 10.1016/j.critrevonc.2022.103806

Abstract

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may reflect the host's pro-inflammatory status and systemic immune response to cancer-related inflammation. We reviewed 22 combined prognostic scores based on peripheral blood-derived inflammatory indices for aNSCLC patients treated with single-agent or combination immune-checkpoint inhibitors (ICI) as first-line or subsequent therapy lines and attempted evidence strength assessment and scoring. The Lung Immune Prognostic Index (LIPI), consisting of derived NLR and LDH, was the most studied score with validated prognostic value in over five thousand aNSCLC ICI-naïve or pretreated patients. The combination of NLR and tumour programmed-cell-death-ligand1 (PD-L1) expression showed a predictive value. The Lung-Immune-Prognostic score (LIPS) might help identify patients with poor performance status but a favourable outcome following first-line ICI. These non-expensive scores can help clinicians discuss the prognosis with aNSCLC patients approaching ICI, identify those less likely to benefit from single-agent ICI and orient future clinical research.

Keywords: Advanced non-small-cell lung cancer; Immune checkpoint inhibitors; Immunotherapy; Inflammatory indices; Lung Immune Prognostic Index; Peripheral blood; Prognostic; Score.

Publication types

Review

MeSH terms

B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms* / pathology
Prognosis

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors